$PTGX

Polycythemia vera market expected to expand 8.9% CAGR through 2036 from $2B base as nine pharma companies advance novel therapies, with rusfertide entering first.

Johnson & Johnson shares dropped under 2% as S&P 500 fell 7%, backed by $94.2B revenue, 6% growth, and 63 consecutive dividend increases, though talc lawsuits and Medicare price negotiations pose headwinds.

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.

BVF Partners liquidated its $170M Protagonist stake despite 120% gains, likely due to changing risk profile as company awaits FDA decision on blood disorder treatment.